Optiquant BKV Quantification Panel for MSSA DNA testing procedures

AcroMetrix, a leading provider of quality control standards for clinical diagnostic laboratories, announced today the launch of the first standardized quality control for MSSA molecular testing.

The OptiQual MSSA Positive Control may be used to independently ensure accuracy and precision through all phases of MSSA DNA testing procedures. AcroMetrix continues to invest in the hospital-acquired infections product family, now offering controls for both MRSA and MSSA. A control for Clostridium difficile will soon be offered as well.

Methicillin-sensitive Staphylococcus aureus (MSSA) is a type of bacteria that is sensitive to certain antibiotics. Staph infections, including those caused by MSSA, occur most frequently among immunocompromised patients in hospitals and healthcare facilities, but can also occur in otherwise healthy people.

“With the urgency currently associated with MRSA and MSSA screening, it is important that hospitals are able to implement tests with the appropriate level of quality control,” said Michael J. Eck, CEO of AcroMetrix. “Many critical and costly patient treatment decisions will be based on the results of these tests so it is crucial that all phases of the testing procedure are properly monitored.”

Each lab can maintain CLIA compliance for qualitative PCR tests that detect MSSA by using the OptiQual MSSA Positive Control daily. The control can also be used as a negative specificity control for MRSA DNA assays, monitoring whether the assay is specific for the mecA gene that distinguishes MRSA from MSSA. This control contains inactivated whole MSSA bacterial particles, providing a safe method of monitoring the entire PCR process from extraction through amplification and detection. Convenient and ready to use, the OptiQual MSSA Positive Control is stored at refrigerated temperatures. This product is for In Vitro Diagnostic Use.